A tsunami of data from the real world, rather than the confines of a controlled clinical trial, is transforming the way medicine is practised. This is principally because it enables money to follow patient outcomes rather than simply the provision of services and treatments. Pharma companies, like every other stakeholder, are on a steep learning curve to make sense of this data and need to know what payers, regulators, healthcare systems and their competitors are also doing in this respect. More than anything, they need perspective to understand what can realistically be achieved with real-world data (RWD) now and in the future. And, given the broad-ranging effects of RWD on healthcare systems, they need to start building bridges between the R&D and commercial sides of their companies, so the RWD effort can be informed by as many people within pharma as possible.
CONTENTS

Foreword .................................................................................................................. 5

Executive Summary .................................................................................................. 6

Interviewees, Figures and Tables ............................................................................. 7

Chapter 1: Why RWD matters to pharma ............................................................... 8
  1.1 Moving into the outcomes business ................................................................. 8
  1.2 The drivers for working with RWD ................................................................. 9
  1.3 Obstacles to working with RWD ..................................................................... 9

Chapter 2: How to enter the RWD conversation .................................................. 10
  2.1 New organisational structures required .......................................................... 10
  2.2 New thinking required .................................................................................... 10
  2.3 Beware the hype .............................................................................................. 11
  2.4 Keep it simple ................................................................................................ 11
  2.5 Low confidence ............................................................................................... 12
  2.6 Urgent need for perspective ........................................................................... 13

Chapter 3: Know the RWD basics ......................................................................... 14
  3.1 An explosion of data sources .......................................................................... 15
     3.1.1 Administrative data held by insurance companies .................................. 15
     3.1.2 National EHR databases ........................................................................ 15
  3.2 Filling the data gaps ......................................................................................... 16
     3.3.1 Registries ................................................................................................. 16
     3.2.2 Pragmatic trials ....................................................................................... 17
     3.2.3 Case study: GlaxoSmithKline’s Salford lung study .................................. 17
     3.2.4 Bespoke patient research ...................................................................... 18
3.3 Solidifying the infrastructures for working with RWD .................................................. 18
  3.3.1 EU PARENT initiative ................................................................. 18
  3.3.1 EU GetReal project ..................................................................... 19
  3.3.2 Massive efforts to link data ........................................................... 20
  3.3.3 Effects of Obamacare ................................................................. 20

Chapter 4: Focus on payers .................................................................................. 21
  4.1 Focus on countries implementing RWD capabilities .............................. 22
  4.2 Registries to restrict access .................................................................. 23
  4.3 Devil resides in the local detail .............................................................. 25
  4.4 RWD application by therapeutic area ....................................................... 25

Chapter 5: Shifts in regulatory thinking ............................................................... 26
  5.1 Adaptive licensing in the EU ............................................................... 26
  5.2 Sentinel Initiative in the US ................................................................. 26

Chapter 6: Collaboration ...................................................................................... 28
  6.1 Proliferation of partnerships ................................................................. 28
  6.2 Return on investment .......................................................................... 29

Chapter 7: Conclusions ...................................................................................... 30
  Key takeaways ......................................................................................... 30

Acknowledgements ......................................................................................... 31

About pharmaphorum media ....................................................................... 32
EXECUTIVE SUMMARY

Real-world data may be over-hyped right now in terms of what it can realistically achieve, but nobody doubts it is the principal means by which healthcare systems will be revolutionised over the next 20 years or so. This is because the real-world picture enables an outcomes-centred approach to take root so healthcare money can deliver value rather than merely provide services and treatments.

But it is not easy to work with RWD, embracing as it does all the human aspects of medicine that are so rigorously deleted from randomised clinical trials. These include patient co-morbidities, lifestyle choices and the fact that patients seldom follow the instructions on the prescription label. Moreover, the datasets that have built up over the years from insurance claims and electronic health records are not always accurate and don’t readily interconnect, being based on different coding systems and relating to the often disparate medical protocols that are practised in the countries or healthcare systems in which they were created. These, and many other challenges, are currently being addressed worldwide as all stakeholders want to work with RWD for their own reasons.

This report focuses on how RWD is currently being used by payers, regulators and pharma companies. It does so from the perspective of pharma people who are not necessarily trained in health economics and outcomes research to enable them to enter the conversation and shape how RWD is used. In that sense it provides a guide to the basics of RWD, such as the rapidly changing market for data, how this data is currently being translated into insights, and the difficulties of striking an appropriate balance between methodologies and cost.

This report provides an overview of why RWD is important to pharma, how the landscape is evolving, and the critical importance of first, talking to payers to find out what they want and, second, building bridges between the commercial and R&D sides of the organisation so RWD can inform every aspect of the business. This includes not only everything from early-stage R&D to market access but also all the opportunities that are evolving for collaborative working.

Pharma companies have never had so many opportunities to enter into partnerships with healthcare organisations, charities, patient communities, physician communities, payers and more. It is for this reason that all departments in pharma companies need to have a feel for the rapidly changing healthcare economies they work in, the shifting mind sets among regulators and payers, and a considered view of how RWD can help them achieve their departmental aims.

These are exciting times and the main message from everyone who contributed to this report is that it is early days. RWD has enormous potential. This is not just in securing market access for drugs, the traction point for most companies to get involved. Nor is it just about improving the efficiency of the R&D process. It is also about what the wealth of RWD coursing round healthcare systems can reveal about patient care. If pharma companies want to be part of that bigger picture they have to at least start thinking about how every one of their departments can access and effectively use the insights revealed by RWD.
ABOUT PHARMAPHORUM MEDIA

PHARMAPHORUM

pharmaphorum facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. We facilitate this using both our publication channels and bespoke consultancy.

Channel offerings

Through pharmaphorum.com and associated social media, we publish thought leadership media from industry experts, healthcare providers and patient organisations to better inform the pharma industry and drive engagement.

Collectively, these channels provide pharma with:

♦ Essential news, opinions and insights
♦ Training / career development
♦ Curated external media, including jobs, events and press releases
♦ Visibility and connectivity with other healthcare stakeholders

For more information please visit: www.pharmaphorum.com/contribute

Consultancy offerings

We support pharma, service providers and broader healthcare organisations to communicate with key stakeholders through high-quality content and truly engaging social media strategies. Clients benefit from our strong networks, first-hand industry experience and access to publication partners. We understand the importance of content and social media engagement as we live and breathe it every day.

Our offerings include:

♦ Engagement strategy
♦ Content production / facilitation
♦ Healthcare / pharma social media
♦ Meetings / round table discussions
♦ Content dissemination

For more information please visit: www.pharmaphorum.com/our-services

PHARMAPHORUM PREMIUM MEDIA

Launched in 2014, pharmaphorum premium media draws on our expert content production capabilities, deep pharma expertise and connectivity across healthcare to publish unique high-value media, which informs pharma industry personnel on critical aspects of their business. Available for purchase by both individuals and organisations, pharmaphorum premium media provides the competitive edge only afforded by access to the opinions and insights of key industry experts.

For more information please visit: www.pharmaphorum.com/premium

www.pharmaphorum.com Tel: +44 (0)1932 339260 Email: info@pharmaphorum.com